Paclitaxel and carboplatin for recurrent salivary gland malignancies

M. Airoldi, G. Fornari, F. Pedani, S. Marchionatti, P. Gabriele, G. Succo, C. Bumma

Research output: Contribution to journalArticlepeer-review


Background: The use of chemotherapy for recurrent salivary gland carcinomas is under investigation. Patients and Methods: Fourteen patients (10 males, 4 females; median age 55 years, range 20 -70) with recurrent carcinomas of major (9 patients) and minor (5 patients) salivary gland origin (histology: 1 adenocarcinoma, 10 adenoid cystic carcinoma, 2 undifferentiated carcinoma, 1 mucoepidermoid carcinoma) were treated with carboplatin AUC 5.5 + paclitaxel 175 mg/m2 (3-hour infusion) on day 1 (interval = 3 weeks). All patients had been previously treated with surgery+radiotherapy and 8 with a cisplatin combination. One patient had a local lesion, 7 loco-regional recurrence and metastases and 6 patients had metastases only. Results: Overall 65 courses were given (median 5; range 2-6). Responses were: PR in 2 patients (14%) lasting 5 and 12 months; 7 NC (50%) with a median duration of 8.5 months (5-12); and 5 PD (36%). The median survival time was 13.5 months for PR/NC patients, 6 months for non responders; median overall survival was 12.5 months (3 - 17+). Conclusion: This combination had a moderate activity; the treatment was well tolerated and toxicity was manageable.

Original languageEnglish
Pages (from-to)3781-3783
Number of pages3
JournalAnticancer Research
Issue number5 C
Publication statusPublished - 2000


  • Carboplatin and adenoid cystic carcinoma
  • Chemotherapy
  • Paclitaxel
  • Salivary gland carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Paclitaxel and carboplatin for recurrent salivary gland malignancies'. Together they form a unique fingerprint.

Cite this